Antipsychotics and the risk of sudden cardiac death. CommentaryRAY, Wayne A; MEREDITH, Sarah; THAPA, Purushottam B et al.Archives of general psychiatry. 2001, Vol 58, Num 12, pp 1161-1171, issn 0003-990XArticle

A Placebo-Controlled Add-On Trial of the Ampakine, CX5I6, for Cognitive Deficits in SchizophreniaGOFF, Donald C; LAMBERTI, J. Steven; LEON, Andrew C et al.Neuropsychopharmacology (New York, NY). 2008, Vol 33, Num 3, pp 465-472, issn 0893-133X, 8 p.Article

Intensive psychosocial intervention enhances functioning in patients with bipolar depression : Results from a 9-month randomized controlled trialMIKLOWITZ, David J; OTTO, Michael W; PATEL, Jayendra et al.The American journal of psychiatry. 2007, Vol 164, Num 9, pp 1340-1347, issn 0002-953X, 8 p.Article

Antidepressant Augmentation Using the N-Methyl-D-Aspartate Antagonist Memantine: A Randomized, Double-Blind, Placebo-Controlled TrialSMITH, Eric G; DELIGIANNIDIS, Kristina M; ULBRICHT, Christine M et al.The Journal of clinical psychiatry. 2013, Vol 74, Num 10, pp 966-973, issn 0160-6689, 8 p.Article

Metabolic profiles of second-generation antipsychotics in early psychosis: Findings from the CAFE studyPATEL, Jayendra K; BUCKLEY, Peter F; WOOLSON, Sandra et al.Schizophrenia research. 2009, Vol 111, Num 1-3, pp 9-16, issn 0920-9964, 8 p.Article

Synthesis and in vitro antibacterial activities of novel oxazolidinonesBRIJESH KUMAR SRIVASTAVA; JAIN, Mukul R; PANDYA, Purvi et al.European journal of medicinal chemistry. 2008, Vol 43, Num 4, pp 683-693, issn 0223-5234, 11 p.Article

New data from the CATIE Trial : The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial : Clinical comparison of subgroups with and without the metabolic syndromeMEYER, Jonathan M; NASRALLAH, Henry A; MCEVOY, Joseph P et al.Schizophrenia research. 2005, Vol 80, Num 1, pp 9-18, issn 0920-9964, 10 p.Article

Effects of hypothermia on myocardial substrate selectionGILBERT, Nathan F; MEYER, Paul E; TAURIAINEN, M. Peter et al.The Annals of thoracic surgery. 2002, Vol 74, Num 4, pp 1208-1212, issn 0003-4975Article

Diaryl Dihydropyrazole-3-carboxamides with Significant In Vivo Antiobesity Activity Related to CB1 Receptor Antagonism : Synthesis, Biological Evaluation, and Molecular Modeling in the Homology ModelBRIJESH KUMAR SRIVASTAVA; JOHARAPURKAR, Amit; PATEL, Harilal et al.Journal of medicinal chemistry (Print). 2007, Vol 50, Num 24, pp 5951-5966, issn 0022-2623, 16 p.Article

Hair growth stimulator property of thienyl substituted pyrazole carboxamide derivatives as a cbl receptor antagonist with in vivo antiobesity effectBRIJESH KUMAR SRIVASTAVA; SONI, Rina; KAPADNIS, Prashant et al.Bioorganic & medicinal chemistry letters (Print). 2009, Vol 19, Num 9, pp 2546-2550, issn 0960-894X, 5 p.Article

Predictors of recurrence in bipolar disorder : Primary outcomes from the systematic treatment enhancement program for bipolar disorder (STEP-BD)PERLIS, Roy H; OSTACHER, Michael J; REILLY-HARRINGTON, Noreen A et al.The American journal of psychiatry. 2006, Vol 163, Num 2, pp 217-224, issn 0002-953X, 8 p.Article

Bioisosteric replacement of dihydropyrazole of 4S-(-)-3-(4-chlorophenyl)-N-methyl-N'-[(4-chlorophenyl)-sulfonyl]-4-phenyl-4,5-dihydro-lH-pyrazole-1-caboxamidine (SLV-319) a potent CB1 receptor antagonist by imidazole and oxazoleBRIJESH KUMAR SRIVASTAVA; SONI, Rina; DHAWAS, Amol et al.Bioorganic & medicinal chemistry letters (Print). 2008, Vol 18, Num 3, pp 963-968, issn 0960-894X, 6 p.Article

Feasibility and Pilot Efficacy Results From the Multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) Randomized Controlled TrialKEEFE, Richard S. E; VINOGRADOV, Sophia; MILLER, Del D et al.The Journal of clinical psychiatry. 2012, Vol 73, Num 7, pp 1016-1022, issn 0160-6689, 7 p.Article